Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 3, 2014

View Archived Issues

Phase II results for the influenza A/H7N9 vaccine in combination with an adjuvant

Shionogi recaps highlights of second quarter of fiscal 2014

Novel genetic biomarkers of human malformation disorders

Sumitomo Dainippon Pharma reviews second quarter of fiscal 2014

Sanofi presents highlights of third quarter 2014

Researchers present novel targets and biomarkers in pancreatic cancer

FDA orphan drug status granted to oprozomib for multiple myeloma

Sodium thiosulfate designated orphan drug by the FDA

Glioma candidate pritumumab receives U.S. orphan drug designation

MPDL-3280A well tolerated in phase Ia trial in patients with mRCC

EMA publishes revised guideline on biosimilars

EMA releases third and final module on influenza vaccine guidance for public consultation

Chugai licenses EpiVax de-immunization technologies to optimize biologics pipeline

Swiss approval to begin Ebola vaccine trial

Award supports Verona Pharma's exploration of RPL-554 for cystic fibrosis

New PDE4B inhibitors reported by Gruenenthal

Esteve presents novel ligands of sigma receptors

Guangzhou Baiyunshan Pharmaceutical synthesizes tricyclic quinolones

Canadian company presents CRP40 fragments for neurological disorders

Glenmark Pharmaceuticals reports novel mPGES-1 inhibitors

New GnRH receptor antagonists discovered at Bayer Schering Pharma

Salix and Pharming launch Ruconest in the U.S. for acute angioedema attacks in HAE

Novartis plans phase I/II trial of Wnt-targeting drug regimen in BRAF-mutant colorectal cancer

Arena Pharmaceuticals to test APD-811 in patients with pulmonary arterial hypertension

Nymox's NX-1207 fails to achieve efficacy endpoints in phase III BPH trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...